These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 30080893

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
    Leoni V, Gatta V, Casiraghi C, Nicosia A, Petrovic B, Campadelli-Fiume G.
    J Virol; 2017 May 15; 91(10):. PubMed ID: 28250120
    [Abstract] [Full Text] [Related]

  • 3. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
    Petrovic B, Leoni V, Gatta V, Zaghini A, Vannini A, Campadelli-Fiume G.
    J Virol; 2018 Mar 15; 92(6):. PubMed ID: 29263257
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors.
    Leoni V, Petrovic B, Gianni T, Gatta V, Campadelli-Fiume G.
    J Virol; 2018 Mar 15; 92(6):. PubMed ID: 29263255
    [Abstract] [Full Text] [Related]

  • 6. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
    Leoni V, Gatta V, Palladini A, Nicoletti G, Ranieri D, Dall'Ora M, Grosso V, Rossi M, Alviano F, Bonsi L, Nanni P, Lollini PL, Campadelli-Fiume G.
    Oncotarget; 2015 Oct 27; 6(33):34774-87. PubMed ID: 26430966
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.
    Reisoli E, Gambini E, Appolloni I, Gatta V, Barilari M, Menotti L, Malatesta P.
    Cancer Gene Ther; 2012 Nov 27; 19(11):788-95. PubMed ID: 22996742
    [Abstract] [Full Text] [Related]

  • 8. Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy.
    Kim Y, Saini U, Kim D, Hernandez-Aguirre I, Hedberg J, Martin A, Mo X, Cripe TP, Markert J, Cassady KA, Dhital R.
    Front Immunol; 2024 Nov 27; 15():1375413. PubMed ID: 38895115
    [Abstract] [Full Text] [Related]

  • 9. Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma.
    Gambini E, Reisoli E, Appolloni I, Gatta V, Campadelli-Fiume G, Menotti L, Malatesta P.
    Mol Ther; 2012 May 27; 20(5):994-1001. PubMed ID: 22354378
    [Abstract] [Full Text] [Related]

  • 10. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.
    Alessandrini F, Menotti L, Avitabile E, Appolloni I, Ceresa D, Marubbi D, Campadelli-Fiume G, Malatesta P.
    Oncogene; 2019 Jun 27; 38(23):4467-4479. PubMed ID: 30755732
    [Abstract] [Full Text] [Related]

  • 11. HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.
    Menotti L, Avitabile E, Gatta V, Malatesta P, Petrovic B, Campadelli-Fiume G.
    Viruses; 2018 Jun 30; 10(7):. PubMed ID: 29966356
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.
    Menotti L, Nicoletti G, Gatta V, Croci S, Landuzzi L, De Giovanni C, Nanni P, Lollini PL, Campadelli-Fiume G.
    Proc Natl Acad Sci U S A; 2009 Jun 02; 106(22):9039-44. PubMed ID: 19458262
    [Abstract] [Full Text] [Related]

  • 14. Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV.
    Gianni T, Leoni V, Sanapo M, Parenti F, Bressanin D, Barboni C, Zaghini A, Campadelli-Fiume G, Vannini A.
    Viruses; 2021 Sep 01; 13(9):. PubMed ID: 34578328
    [Abstract] [Full Text] [Related]

  • 15. Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV.
    Vannini A, Parenti F, Bressanin D, Barboni C, Zaghini A, Campadelli-Fiume G, Gianni T.
    Viruses; 2021 Oct 16; 13(10):. PubMed ID: 34696515
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Retargeting Strategies for Oncolytic Herpes Simplex Viruses.
    Campadelli-Fiume G, Petrovic B, Leoni V, Gianni T, Avitabile E, Casiraghi C, Gatta V.
    Viruses; 2016 Feb 26; 8(3):63. PubMed ID: 26927159
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.